Apatinib Mesylate
Pre-clinicalRecruiting 0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent Atypical/malignant Meningioma
Conditions
Recurrent Atypical/malignant Meningioma
Trial Timeline
Aug 18, 2020 → Aug 31, 2025
NCT ID
NCT04501705About Apatinib Mesylate
Apatinib Mesylate is a pre-clinical stage product being developed by Brain Biotech for Recurrent Atypical/malignant Meningioma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04501705. Target conditions include Recurrent Atypical/malignant Meningioma.
What happened to similar drugs?
6 of 20 similar drugs in Recurrent Atypical/malignant Meningioma were approved
Approved (6) Terminated (0) Active (14)
Hype Score Breakdown
Clinical
3
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04501705 | Pre-clinical | Recruiting |
Competing Products
20 competing products in Recurrent Atypical/malignant Meningioma